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Abstract
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is thought to affect about 1 in 1000 people in the UK.
ADPKD causes a progressive decline in kidney function, with kidney failure tending to occur in middle age. Children
and young people with ADPKD may not have any symptoms. However they may have high blood pressure, which
may accelerate progression to later stages of chronic kidney disease.
There is uncertainty and variation in how health professionals manage children and young people with confirmed
or a family history of ADPKD, because of a lack of evidence. For example, health professionals may be unsure about
when to test children’s blood pressure and how often to monitor it in the hospital clinic or at the GP. They may
have different approaches in recommending scanning or genetic testing for ADPKD in childhood, with some
recommending waiting until the young person is mature enough to make this decision his or herself.
This guideline is intended to help families affected by ADPKD by making sure that:
 health professionals with specialist knowledge in ADPKD offer you information on inheritance and potential
benefits and harms of testing for ADPKD.
 the decision to test and the method of testing for ADPKD in children and young people is shared between
you or your family and the health professionals
 blood pressure assessment is undertaken regularly in children and young people at risk of developing ADPKD
Method used to arrive at a recommendation
Evidence reviews were undertaken that focused on literature
in relation to children and young people (CYP) with, or are
at risk of developing Autosomal Dominant Polycystic Kidney
Disease (ADPKD). Medline (1980 – December 2017),
EMBASE (1980 – December 2017) and PsychInfo data-
bases were searched as well as websites of national
associations in this field. A search strategy was developed
by the guideline committee to ensure that all papers
addressing the questions were identified using search
terms based on PICO methodology (Table 1). The clinical
leads also hand searched reference lists of reviews and
included papers.
Abstracts were screened for relevance by a clinical lead
and 1 other member of the guideline committee according
to pre-defined inclusion and exclusion criteria as detailed
in the scope. Abstracts identified for review by the two
reviewers were compared and any disputed abstracts were
resolved by the guideline committee. The full papers were
then reassessed by the clinical lead to further exclude any
study that does not meet the following predefined criteria:
Randomised controlled trials (RCT), non-randomised
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studies if adjusted for key confounders (age, health at
baseline, co-morbidities).
Clinicians on the guideline committee critically appraised
any eligible papers using critical appraisal skills programme
tools [1]. Where evidence was lacking, formal Delphi
consensus methodology was employed. A Delphi panel
was constituted, comprising representation from each
specialist area covered by the guideline: Nephrology
services (3 adult and 3 paediatric nephrologists), cli-
nical genetics (3 representatives), paediatrics with an
interest in nephrology (3 representatives), lay members (3)
and general practitioners (3 invited, 2 responded). A Likert
scale was used for panellists to provide their responses to
statements. Consensus agreement and disagreement was
defined as 80% of panellists selecting ‘agree’ or ‘disagree’
respectively. Individual responses were anonymised to
panellists and the working group, with the exception of
the chair. No literature was sent to participants to avoid
risk of bias. The process was iterative (participants able to
change their views in subsequent rounds). Three rounds
were undertaken.
Background
This guideline makes recommendations for monitoring
children and young people (CYP) up to 18 years of
age with, or at risk of developing Autosomal Dominant
Polycystic Kidney Disease (ADPKD).
ADPKD is the commonest inherited renal disease with
an incidence of around 1 in 1000 and accounts for 5–7%
of adults commencing renal replacement therapy [2, 3].
Whilst ADPKD has traditionally been thought of as an
adult disease, with established renal failure tending to
occur in or after the 6th decade, there is clear evidence
of earlier manifestation in children and young people
(CYP), in whom hypertension and proteinuria may
accelerate progression to later stages of chronic kidney
disease. There is wide variation in clinical practice facing
CYP with confirmed or a family history of ADPKD,
with regard to a) assessment of blood pressure and
urine testing for the presence of proteinuria b) ultra-
sound testing to evaluate presence of cysts and c) genetic
counselling and testing. In order to improve quality
of care and reduce variation in practice, the British
Association for Paediatric Nephrology (BAPN) and
the UK Renal Association (RA) in collaboration with
key partners, has undertaken this work to develop
best practice guidance in the area.
Summary of clinical practice guidelines
Guideline 1
We recommend that parents or carers of children at risk
of developing ADPKD should be offered information on
ADPKD inheritance and potential benefits and harms of
testing for ADPKD, by health professionals with specialist
knowledge in this area. (1D).
Guideline 2
We recommend that children and young people aged
5 years and above with, or at risk of developing ADPKD,
should have an assessment of blood pressure (BP) at least
once every 2 years. (1B).
Guideline 3
We recommend that the decision to test for ADPKD in
asymptomatic children and young people (CYP) at risk
of developing ADPKD, should be undertaken jointly
between health professionals and parents or carers and,
wherever possible, the young person. (1D).
Guideline 4
If testing is decided on, we suggest that either kidney
ultrasound or genetic testing may be offered to asymp-
tomatic children and young people at risk of ADPKD,
where testing has been agreed by parents or carers
(and, wherever possible, the young person) and health
professionals (2D).
Guideline 5
We suggest that, if asymptomatic children at risk of ADPKD
do not have cysts on ultrasound, further ultrasound testing
should be deferred until adolescence (15–18 years), or
later if preferred by the young person (2D).
Guideline 6
We recommend that if genetic testing is planned in
children and young people at risk of ADPKD, identifi-
cation of the mutation in the affected adult family
member (if not already known) should be undertaken
prior to testing the child or young person. (1D).
Table 1 PICO characteristics
Population Intervention Comparison Outcome Study design
Children (< 18) with a confirmed
diagnosis of ADPKD or at risk of
ADPKD due to their family history
Ultrasonography
Cranial imaging
Blood Pressure
monitoring
Monitoring for albuminuria
Therapeutics
Genetic counselling
Any intervention
compared with any other
or no intervention
Mortality
Hospitalisations
Chronic Kidney
Disease
Cardiovascular
disease
Hypertension
Randomised controlled trials (RCT)
Non-randomised studies if adjusted
for key confounders (age, health at
baseline, co-morbidities).
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Summary of audit measures
 Audit Measure 1: Proportion of parents or carers
of children at risk of developing ADPKD offered
information on ADPKD inheritance and potential
benefits and harms of testing for ADPKD
 Audit Measure 2: Proportion of children and
young people aged 5 years and above with, or at risk
of developing ADPKD, having an assessment of
blood pressure (BP) at least once every 2 years
 Audit Measure 3: Proportion of asymptomatic
children and young people at risk of developing
ADPKD offered testing for ADPKD
 Audit Measure 4:
a. Proportion of asymptomatic children and young
people at risk of developing ADPKD offered
genetic testing for ADPKD
b. Proportion of asymptomatic children and young
people at risk of developing ADPKD offered
ultrasound testing for ADPKD
 Audit Measure 5: Proportion of asymptomatic
children at risk of ADPKD who do not have cysts
on ultrasound, having repeated ultrasound testing
prior to adolescence (15–18 years)
 Audit Measure 6: Proportion of asymptomatic
children at risk of ADPKD whose parents have been
tested for a genetic mutation prior to the child being
tested
Summary of research recommendations
Research recommendation 1: In children and young
people with ADPKD, does regular (e.g. yearly or every 2
years) urine albumin: creatinine monitoring and treat-
ment reduce disease progression?
Research recommendation 2: In children and young
people with ADPKD what is a) the incidence of
sub-arachnoid haemorrhage and b) the prevalence of
intracranial aneurysm?
Research recommendation 3: In adults, children
and young people with ADPKD with a family history
of intracranial aneurysm or sub-arachnoid haemorrhage
does Intracranial Magnetic Resonance (MR) imaging
reduce the risk of intracranial events?
Rationale for clinical practice guidelines
Guideline 1
We recommend that parents or carers of children and
young people at risk of developing ADPKD should be
offered information on ADPKD inheritance and poten-
tial benefits and harms of testing for ADPKD, by health
professionals with specialist knowledge in this area. (1D)
 Audit Measure 1: Proportion of parents or carers
of children at risk of developing ADPKD offered
information on ADPKD inheritance and potential
benefits and harms of testing for ADPKD
Rationale
No relevant studies were identified for this review ques-
tion; however, NICE guidance on patient experience in
adult NHS services recommends that patients should be
provided with information, and the support they need to
promote their active participation in care and self-man-
agement. This should include information about relevant
treatment options and services that they are entitled to,
even if these are not provided locally [4]. There was
100% agreement with this recommendation in the Delphi
consensus process. Health professionals should be aware
of the anxiety suffered by families relating to uncertainty
of diagnosis as well as at times of testing for ADPKD.
Health professionals should discuss the limitations of test-
ing modalities for ADPKD. Renal ultrasound cannot effect-
ively exclude ADPKD in children [5]. In a retrospective
cohort study of ultrasound assessment in children and
young people under the age of 15 at risk of ADPKD, 193/
420 CYP were diagnosed with cysts at baseline visit (mean
age 8.6 +/− 4.2 years) with 227 having no cysts (8.0 ± 4.1
years). In follow up to age fifteen, 18/77 (23%) of the latter
group who underwent repeat ultrasound developed cysts. In
other words, 23% of CYP with no cysts visible on initial
renal ultrasound who received a further ultrasound, were di-
agnosed with ADPKD [6]. No standardised criteria for renal
ultrasound diagnosis of ADPKD exist for children under the
age of 15 years, and even below the age of 30, there is a sig-
nificant false negative rate. This is particularly so in families
carrying a PKD2 mutation, which is typically associated
with milder disease. In these families, 16.5% of patients
between the ages of 15–29, with no cysts on initial ultra-
sound scan, go on to a diagnosis of ADPKD later in life
[7]. While genetic testing is more definitive, it is most
likely to be informative in families of known genotype, as
around 10% of families phenotypically affected by ADPKD
do not carry a pathogenic mutation of PKD1 or PKD2 that
is detected by current technologies [8]. Health profes-
sionals (generally nephrologists, geneticists or paediatri-
cians with interest in nephrology) providing information
on testing should have a good understanding of these
issues.
Guideline 2
We recommend that children and young people aged 5
years and above with, or at risk of developing ADPKD,
should have an assessment of blood pressure (BP) at
least once every 2 years. (1B).
Audit Measure 2: Proportion of children and young
people aged 5 years and above with, or at risk of developing
ADPKD, having an assessment of blood pressure (BP) at
least once every 2 years.
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Rationale
Low quality evidence identified for this review question
was deemed by the committee to be sufficient to make a
recommendation without the need for formal consensus.
A recent systematic review of 928 children with ADPKD
across 14 studies estimated the prevalence of hyper-
tension to be 20% (95% CI 15–27%) [9]. There is also
evidence to suggest that children with ADPKD whose
BP is high or borderline high have an increased left
ventricular mass index on echocardiography, a marker
of cardiac target organ damage [10]. Studies have also
shown that children with ADPKD who are hypertensive
show an increased total kidney volume, compared to
those that are normotensive [11–13]. There are, as yet,
no studies assessing long term outcomes for the treat-
ment of hypertension in children with ADPKD. How-
ever, there is clear evidence of benefit of treating
hypertension in children generally and especially in
those with chronic kidney disease [14].
We recommend that both children with a confirmed
diagnosis of ADPKD and those at risk of ADPKD
through family history should have BP monitored, since
some families may choose not to undertake testing for
ADPKD in childhood. The risk of developing hyperten-
sion in children with ADPKD rises with age [9]. Hyperten-
sion under the age of 5 years is uncommon in ADPKD
[15] and should prompt a search for an alternative diagno-
sis. In the absence of any other disease process BP rises
slowly in children with ADPKD, therefore monitoring BP
every 2 years should be sufficient to detect a rise in BP
requiring treatment during childhood.
Guideline 3
We recommend that the decision to test for ADPKD in
asymptomatic children and young people (CYP) at risk
of developing ADPKD, should be undertaken jointly
between health professionals and parents or carers and,
wherever possible, the young person. (1D).
Audit Measure 3: Proportion of asymptomatic children
and young people at risk of developing ADPKD offered
testing for ADPKD.
Rationale
No relevant studies were identified for this review ques-
tion. There was 88% agreement with this recommenda-
tion in the Delphi consensus process.
Inheriting and passing on a genetic disease may have
significant psychological impact, ranging from frank
depression through anxiety, guilt, anger, uncertainty and
sadness [16]. This genetic anxiety or ‘guilt’ may increase
with uncertainty over disease variability and where there
is a perceived lack of diagnosis or effective therapy.
These are common issues in CYP with ADPKD, which
may be further compounded by mixed messages from
the medical community, with conflicting opinions as to
the clinical significance of ADPKD in childhood. Genetic
Counselling and testing for a condition in at risk individ-
uals has been reported to ameliorate the psychological
burden for some families and children [17–19], however,
wherever possible, the child or young person should be
involved in this decision. Article 12 of the United
Nations Convention on the Rights of the Child (1989)
states that we must assure ‘the child who is capable of
forming his or her own views has the right to express
those views freely’ and that ‘the views are given due
weight in accordance with the age and maturity of the
child’ [20].
Important issues to be discussed in counselling before
deciding to test for ADPKD include:
 Age and ‘Gillick’ competence of the CYP and
consideration of whether to wait until they can
make a fully-informed decision.
 Risk of false negative results for ultrasound and
genetic tests as described on page 9
 Implications for ongoing management. Blood
pressure monitoring is likely to be as important as
making the diagnosis in preventing long term
complications, but this should be balanced against
the psychological benefits of confirming / refuting
(noting risk of false negative results) ADPKD. The
discussion is likely to change when new treatments
become available for children and young people
with ADPKD.
A recent European ADPKD Forum multidisciplinary
position statement states that ‘Individuals with ADPKD
should have access to lifelong, multidisciplinary, specialist
and patient-centred care, with information and support to
help patients and their families act as fully informed and
active partners in care [21].
Guideline 4
If testing is decided on, we suggest that either kidney
ultrasound or genetic testing may be offered to asymp-
tomatic children and young people at risk of ADPKD,
where testing has been agreed by parents or carers
(and, wherever possible, the young person) and health
professionals (2D).
Audit Measure 4:
a. Proportion of asymptomatic children and young
people at risk of developing ADPKD offered genetic
testing for ADPKD
b. Proportion of asymptomatic children and young
people at risk of developing ADPKD offered
ultrasound testing for ADPKD
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Rationale
No relevant studies comparing outcomes in CYP at risk
of ADPKD undergoing genetic versus ultrasound testing
for ADPKD were identified for this review question.
There was 70% agreement with this recommendation
(statement) by the Delphi panellists, i.e. consensus not
reached. Areas for disagreement largely related to
concerns about the utility of ultrasound, particularly in
younger children with no standardised criteria for renal
ultrasound diagnosis of ADPKD under the age of 15
years and significant false negative rates [22]. The
importance of involving CYP in the decision making
process was also noted in the Delphi responses. The
committee believed that to offer genetic but not ultra-
sound testing to asymptomatic children and young
people at risk of ADPKD could result in a significant
change in practice in the absence of evidence and that
the importance of individual choice between the two
testing modalities should be emphasised given the lack
of clear superiority of one over the other. The commit-
tee also noted that, although not reaching consensus,
the majority (70%) of panellists supported offering a
choice of kidney ultrasound or genetic testing to asymp-
tomatic CYP at risk of ADPKD, where testing has been
agreed by parents or carers and health professionals
(and, wherever possible, the young person) and agreed
to make a weaker ‘we suggest’ recommendation.
Guideline 5
We suggest that, if asymptomatic children at risk of
ADPKD do not have cysts on ultrasound, further ultra-
sound testing should be deferred until adolescence (15–
18 years), or later if preferred by the young person (2D).
Audit Measure 5: Proportion of asymptomatic chil-
dren at risk of ADPKD who do not have cysts on ultra-
sound, having repeated ultrasound testing prior to
adolescence (15–18 years).
Rationale
No relevant studies assessing outcomes in asymptomatic
children at risk of ADPKD undergoing repeated ultra-
sound testing for ADPKD, compared with those not
undergoing repeated ultrasound testing, were identified
for this review question. There was 70% agreement with
this recommendation (statement) by the Delphi panel-
lists, i.e. consensus not reached. Areas for disagreement
largely related to the age of the child at the time of the
first negative ultrasound scan and a preference to
perform more regular ultrasound scans if requested by
parents. There may also be concern by health professionals
about the risk of missing very early onset ADPKD, how-
ever, these children comprise less than 1% of cases and are
likely to be genetically distinct from typical ADPKD,
perhaps with multiple compound mutations combining to
generate such an aggressive phenotype [23, 24]. This
recommendation does not apply to these children, who
undergo diagnostic testing for symptomatic disease (e.g.
severe renal enlargement, hypertension) and are found to
have radiological abnormalities at presentation.
Repeated ultrasound testing is not routinely under-
taken in adults with ADPKD where significant progres-
sion usually occurs over decades. In the absence of
evidence of benefit of repeated ultrasound testing in
asymptomatic CYP, together with its resource implica-
tions, and the importance of considering the wishes of
the young person in the decision making process where
possible, the committee was of the view that a recom-
mendation for repeated ultrasound testing prior to ado-
lescence could not be made. The committee considered
whether repeated ultrasound testing might help to alle-
viate parental anxiety, but noted in their experience that
repeated ultrasound testing may also add to the psycho-
logical burden for families.
The committee also noted that, although not reaching
consensus, the majority (70%) of panellists supported
deferring further ultrasound testing until adolescence
(15–18 years, or later if preferred by the young person) in
asymptomatic children at risk of ADPKD who do not have
cysts on initial ultrasound. The committee therefore
agreed to make a weaker ‘we suggest’ recommendation.
Guideline 6
We recommend that if genetic testing is planned in
children and young people at risk of ADPKD, identification
of the mutation in the affected adult family member (if not
already known) should be undertaken prior to testing the
child or young person. (1D).
Audit Measure 6: Proportion of asymptomatic chil-
dren at risk of ADPKD whose parents have been tested
for a genetic mutation prior to the child being tested.
Rationale
No relevant studies were identified for this review ques-
tion. There was 88% agreement with this recommendation
in the Delphi consensus process. ADPKD is associated
with a wide range of mutations in the genes PKD1 and
PKD2, many of which occur only in one family [25]. As a
result, genetic testing of PKD1 and PKD2 can find
sequence variations that have not been previously
described, and it can be difficult to determine the patho-
genicity of these changes. First identifying the mutation in
the affected adult family member allows for the use of
segregation analysis to help assign pathogenicity to
any mutations identified in the child or young person.
Furthermore, up to 10% of ADPKD is not associated with
detectable mutations in PKD1 or PKD2 [8]. This means
that failure to identify a PKD1 or PKD2 mutation in a
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predictive genetic test cannot reliably exclude ADPKD,
unless the familial mutation is known be in those genes.
Rationale for research recommendations
Research recommendation 1: In children and young
people with ADPKD does regular (e.g. yearly or every 2
years) urine albumin: creatinine monitoring and treat-
ment improve outcome?
Rationale
The guideline committee was not able to make a recom-
mendation on monitoring of urine albumin: creatinine
in CYP with ADPKD or at risk of ADPKD. No relevant
studies assessing outcomes in CYP with proteinuria were
identified and no consensus was achieved in 2 rounds of
the Delphi survey; only 41% of panellists agreed with the
statement ‘Urine protein estimation (best assessed at
urine albumin:creatinine) should be offered at least every
2 years to children and young people with confirmed
ADPKD commencing at 5 years of age’. The prevalence
of proteinuria in CYP with ADPKD has been reported to
be as high as 20% [9], however, a number of studies have
failed to show a relationship between hypertension and
proteinuria in children with ADPKD [9, 11, 26]. In
adults with ADPKD, established proteinuria and
microalbuminuria are reported to be associated with
increased mean arterial pressure and more severe
renal cystic involvement [27, 28].
Research recommendation 2: In children and young
people with ADPKD what is a) the incidence of sub-
arachnoid haemorrhage and b) the prevalence of intra-
cranial aneurysm?
Research recommendation 3: In adults, children and
young people with ADPKD with a family history of
intracranial aneurysm or sub-arachnoid haemorrhage
does Intracranial Magnetic Resonance (MR) imaging
reduce the risk of intracranial events?
Rationale
The guideline committee was not able to make a recom-
mendation on MR imaging in CYP with ADPKD or at
risk of ADPKD. No relevant studies examining whether
neurological imaging in CYP with ADPKD and a family
history of intracranial events is associated with reduced
cardiovascular morbidity compared with those who do
not have neurological imaging, were identified. Three
individual case reports of people under 18 years with
ADPKD with intracranial events were found but did not
meet inclusion criteria.
No consensus was achieved in 2 rounds of the Delphi
survey; 61% of panellists agreed with the statement
‘Intracranial Magnetic Resonance (MR) imaging should
be offered to CYP with ADPKD with a family history of
intracranial aneurysm or sub-arachnoid haemorrhage’
(round 1), whilst 41% agreed with the statement ‘Intra-
cranial Magnetic Resonance (MR) imaging should not
routinely be offered to CYP with ADPKD even with a
family history of intracranial aneurysm or sub-arachnoid
haemorrhage’ (round 2). The lack of published data
around screening in CYP < 18y was acknowledged and
concern was noted with regard to thresholds for neuro-
surgical intervention if intracranial aneurysms were
identified in CYP as a result of such testing.
A systematic review by Vlak et al. [29] estimated an
overall prevalence of unruptured intracranial aneurysms
(ICA) of 3.2% in a population without comorbidity. They
calculated a prevalence ratio (PR) of 6.9 (95%CI 3.5–14)
in patients with ADPKD compared to the population
without comorbidity. Further analysis showed that the
PR for patients with ADPKD and a family history of
SAH or UIA was 2.0 (95%CI 0.5–7.4) compared with
patients with ADPKD but no family history of SAH or
UIA. The committee agreed that studies assessing the
prevalence of SAH and ICA in CYP < 18y with ADPKD
should be undertaken prior to making recommendations
in this area.
Lay summary
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
is thought to affect about 1 in 1000 people in the UK.
ADPKD causes a progressive decline in kidney function,
with kidney failure tending to occur in middle age.
Children and young people with ADPKD may not have
any symptoms. However they may have high blood
pressure, which may accelerate progression to later
stages of chronic kidney disease.
There is uncertainty and variation in how health pro-
fessionals manage children and young people with
confirmed or a family history of ADPKD, because of a
lack of evidence. For example, health professionals may
be unsure about when to test children’s blood pressure
and how often to monitor it in the hospital clinic or at
the GP. They may have different approaches in recom-
mending scanning or genetic testing for ADPKD in
childhood, with some recommending waiting until the
young person is mature enough to make this decision
his or herself.
This guideline is intended to help families affected by
ADPKD by making sure that:
 health professionals with specialist knowledge in
ADPKD offer you information on inheritance and
potential benefits and harms of testing for ADPKD.
 the decision to test and the method of testing for
ADPKD in children and young people is shared
between you or your family and the health
professionals
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 blood pressure assessment is undertaken regularly in
children and young people at risk of developing
ADPKD
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